Observational study to evaluate acceptability and bleeding profile with Drospirenone 4 mg, in a regimen of use 24/4 in contraception (Slinda®, Exeltis HealthCare) after six months of use.
- Conditions
- Z30Contraceptive management
- Registration Number
- DRKS00025993
- Lead Sponsor
- Exeltis Healthcare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 300
Inclusion Criteria
1.Women over 18 years up to 50 years.
2. They use Slinda ® for the approved indication (contraception) and have started treatment at least 6 months before the visit.
3. They shall give informed consent in order to participate in the study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of the effect of Slinda on user acceptance after six months of treatment.
- Secondary Outcome Measures
Name Time Method (a)description of the bleeding profile.<br>(b) tolerability and safety assessment.<br>